| 慢性粒细胞白血病的发病机制及治疗现状 |
| |
| 引用本文： | 陈彭. 慢性粒细胞白血病的发病机制及治疗现状[J]. 白血病．淋巴瘤, 2016, 25(8): 509-512. DOI: 10.3760/cma.j.issn.1009-9921.2016.08.018 |
| |
| 作者姓名： | 陈彭 |
| |
| 作者单位： | 第四军医大学唐都医院血液内科,西安,710038 |
| |
| 基金项目： | 陕西省科技发展攻关计划(2013K12-06-02)Key Project for Science and Technology Development of Shaanxi Province (2013K12-06-02) |
| |
| 摘 要： | 慢性粒细胞白血病(CML)是一种发生在骨髓多功能造血干细胞上的恶性增殖性疾病.目前,伊马替尼用于CML的一线治疗,不但对慢性期的患者疗效显著,而且对于加速期和急变期患者也同样能够明显延长其生存时间.随着伊马替尼在临床上的长期应用,逐渐出现了耐药及不耐受现象,因此降低了CML的长期治疗效果.文章就CML的发病机制及治疗现状进行综述.
|
| 关 键 词： | 白血病,髓样,慢性 酪氨酸激酶抑制剂 bcr-abl |
Pathogenesis and treatment of chronic myeloid leukemia: current status |
| |
| Abstract: | Chronic myeloid leukemia (CML) is a malignant clonal proliferative disease,which originates from multifunctional hematopoietic stem cells of bone marrow.Imatinib is used as the first-line treatment for CML currently,owing to its obvious curative effect for patients in chronic phase and survival time prolonged significantly for patients in accelerated phase and blast crisis.With the long-term application of imatinib in clinic,the drug resistance and intolerance gradually appear,resulting in decreased long-term effects of CML.This paper will review the current status of the pathogenesis and treatment of CML. |
| |
| Keywords: | Leukemia,myelogenous,chronic Tyrosine kinase inhibitors bcr-abl |
| 本文献已被 万方数据 等数据库收录！ |
|
